Nitric oxide in breast cancer: Induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1201-1207

  Nakamura, Yasushi ^a   Yasuoka, Hironao ^a   Tsujimoto, Masahiko ^b   Yoshidome, Katsuhide ^b   Nakahara, Masaaki ^b   Nakao, Kazuyasu ^b   Nakamura, Misa ^a   Kakudo, Kennichi ^a,b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 (HYDROXYNITROSOHYDRAZONO)BISETHANAMINE; 3 NITROTYROSINE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; PEROXYNITRITE; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ALKENES; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 33644772212     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1269     Document Type: Article

References (25)

1. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002;12: 311-20.
2. Ambs S, Merriam WG, Ogunfusika MO, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998;4:1371-6.
3. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-44.
4. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
5. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20:672-82.
6. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91
7. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
8. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor d in breast carcinoma with long-term follow-up. Clin Cancer Res 2003;9:716-21.
9. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005;91:125-32.
10. Yasuoka H, Nakamura Y, Zuo H, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 2005;18:1127-33.
11. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998;95:14389-94.
12. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566-70.
13. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000;14:2087-96.
14. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003;16:309-14.
15. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993; 214:11-6.
16. Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press: 2003.
17. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
18. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
19. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-58.
20. Edwards P, Cendan JC, Topping DB, et al. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J Surg Res 1996;63:49-52.
21. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5:74-80.
22. Samoszuk M, Brennan ML, To V, et al. Association between nitrotyrosine levels and microvascular density in human breast cancer. Breast Cancer Res Treat 2002;74:271-8.
23. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998;273:8413-8.
24. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem 2003;278:5750-9.
25. Su JL, Shih JY, Yen ML, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004;64:554-64.